A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Inclusion Criteria:

- Signed a current IRB-approved informed consent form

- Successful completion of a prior double blind study of ADS-5102 in patients with MS
walking impairment.

Exclusion Criteria:

- Based on the judgment of the investigator or Medical Monitor, participation in the
study would jeopardize the safety of the subject.

- If female, is pregnant or lactating

- If a sexually active female, is not surgically sterile or at least 2 years
post-menopausal, or does not agree to utilize a highly effective hormonal method of
contraception (an IUD, or vasectomized male partner is also acceptable), in
combination with a barrier method, from baseline through at least 4 weeks after the
completion of study treatment. If a sexually active male, does not agree to utilize
condoms from screening through at least 4 weeks after the completion of study
treatment.

- Anticipated treatment with any amantadine formulation other than ADS-5102

- Planned participation in another interventional clinical trial